Redhill Biopharma
RDHL
31 hedge funds and large institutions have $18M invested in Redhill Biopharma in 2017 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 2 increasing their positions, 8 reducing their positions, and 6 closing their positions.
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
35% more funds holding
Funds holding: 23 → 31 (+8)
0% more ownership
Funds ownership: 0% → 0% (+0%)
7% less capital invested
Capital invested by funds: $19.5M → $18M (-$1.43M)
75% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$6.73M |
| 2 |
Creative Planning
Overland Park,
Kansas
|
+$943K |
| 3 |
VF
Virtu Financial
New York
|
+$411K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$236K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$222K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BHB
Bank Hapoalim BM
Tel Aviv,
Israel
|
-$1.47M |
| 2 |
FM
Family Management
New York
|
-$408K |
| 3 |
Millennium Management
New York
|
-$212K |
| 4 |
ISL
Ingalls & Snyder LLC
New York
|
-$202K |
| 5 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
-$33.7K |
RDHL Hedge Fund Activity: Q4 2017 in Review
31 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q4 2017, worth a combined $18M — down 7.3% from $19.5M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new RDHL positions and 6 closed out — a net gain of 8 holders — while 2 added to existing stakes and 8 trimmed.
The largest buyer was 683 Capital Management, opening a new position worth an estimated $6.73M. The largest seller was Bank Hapoalim BM, exiting entirely with an estimated $1.47M sold.
- 31 institutional investors held Redhill Biopharma (RDHL) as of Q4 2017, up from 23 in Q3 2017.
- Funds reported $18M of Redhill Biopharma stock for Q4 2017, down 7.3% quarter-over-quarter.
- 14 funds opened new Redhill Biopharma positions in Q4 2017 and 6 closed out, a net change of +8 holders.
- The largest Redhill Biopharma buyer in Q4 2017 was 683 Capital Management, an estimated $6.73M added.
- The largest Redhill Biopharma seller in Q4 2017 was Bank Hapoalim BM, an estimated $1.47M sold.
Based on aggregated 13F filings for Q4 2017.